Relapsed or Refractory Acute Myeloid Leukemia
Oncology
4
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AntengeneSelinexor
Merck & Co.MK-0482
AmgenAMG 330
iBioPHI-101
Clinical Trials (4)
Total enrollment: 14 patients across 4 trials
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Start: Jan 2023Est. completion: Dec 2024
Phase 3Recruiting
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
Start: Sep 2021Est. completion: Dec 202313 patients
Phase 1Terminated
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Start: Sep 2020Est. completion: Oct 20201 patients
Phase 1Terminated
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
Start: Jun 2020Est. completion: May 2022
Phase 1Unknown
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3m ago
Office Administrator
SystImmune
3m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
14m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
17m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
17m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 14 patients
4 companies competing in this space